Core Viewpoint - Foghorn Therapeutics Inc. is participating in the Guggenheim Emerging Outlook: Biotech Summit, highlighting its innovative Gene Traffic Control platform aimed at treating serious diseases, particularly in oncology [1]. Group 1: Company Overview - Foghorn Therapeutics is a clinical-stage biotechnology company focused on developing a new class of medicines that correct abnormal gene expression [1]. - The company utilizes its proprietary Gene Traffic Control platform to identify and validate drug targets within the chromatin regulatory system [3]. - Foghorn is developing multiple product candidates specifically in the oncology sector [3]. Group 2: Event Participation - Management will present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026, at 3:00 p.m. EST [2]. - A webcast of the presentation will be available for 30 days on the company's website [2]. - The management team will also engage in one-on-one meetings during the summit [4].